Astera Labs, Inc. $ALAB Stake Raised by Value Aligned Research Advisors LLC

Value Aligned Research Advisors LLC raised its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 16.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,378,351 shares of the company’s stock after acquiring an additional 197,320 shares during the quarter. Astera Labs accounts for about 3.3% of Value Aligned Research Advisors LLC’s portfolio, making the stock its 12th biggest holding. Value Aligned Research Advisors LLC’s holdings in Astera Labs were worth $269,881,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Astera Labs by 14.1% during the third quarter. Vanguard Group Inc. now owns 13,743,141 shares of the company’s stock valued at $2,690,907,000 after purchasing an additional 1,693,918 shares during the last quarter. State Street Corp grew its position in Astera Labs by 9.1% in the third quarter. State Street Corp now owns 2,339,451 shares of the company’s stock worth $458,065,000 after buying an additional 195,992 shares during the last quarter. 1832 Asset Management L.P. increased its holdings in shares of Astera Labs by 151.4% in the second quarter. 1832 Asset Management L.P. now owns 1,543,500 shares of the company’s stock valued at $139,563,000 after buying an additional 929,600 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Astera Labs by 46.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,507,675 shares of the company’s stock valued at $295,203,000 after acquiring an additional 479,360 shares during the last quarter. Finally, Amundi boosted its stake in shares of Astera Labs by 1,298.6% during the 3rd quarter. Amundi now owns 1,421,263 shares of the company’s stock worth $278,283,000 after acquiring an additional 1,319,643 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Analyst Ratings Changes

ALAB has been the topic of a number of recent research reports. Barclays set a $165.00 target price on Astera Labs in a report on Thursday, January 15th. Citigroup decreased their price target on Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, February 11th. Weiss Ratings cut Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. BNP Paribas Exane initiated coverage on shares of Astera Labs in a research note on Thursday, November 20th. They set an “outperform” rating for the company. Finally, Northland Securities raised their target price on shares of Astera Labs from $175.00 to $195.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $202.22.

Insider Activity at Astera Labs

In other news, CEO Jitendra Mohan sold 94,971 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $11,758,359.51. Following the transaction, the chief executive officer owned 1,452,739 shares in the company, valued at $179,863,615.59. This represents a 6.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jack R. Lazar sold 7,500 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $119.80, for a total transaction of $898,500.00. Following the completion of the sale, the director directly owned 87,351 shares of the company’s stock, valued at $10,464,649.80. This trade represents a 7.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 226,792 shares of company stock worth $28,001,069. Company insiders own 12.50% of the company’s stock.

Astera Labs Stock Down 1.0%

Shares of Astera Labs stock opened at $126.34 on Thursday. The stock has a market cap of $21.50 billion, a PE ratio of 103.56, a price-to-earnings-growth ratio of 2.51 and a beta of 1.74. The business has a fifty day simple moving average of $145.64 and a 200-day simple moving average of $166.93. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.07. The firm had revenue of $270.58 million for the quarter, compared to analyst estimates of $249.46 million. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.Astera Labs’s quarterly revenue was up 91.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.37 earnings per share. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.